1 0
Cart
    Inquiry
    Popular Searches: Recombinant Antibody MHC Tetramer T cell Receptor Scaffold Protein

    Anti-C3 Recombinant Antibody Products

    Loading...

    Anti-C3 Products

    + Filter
    Loading...
    View More Products

    Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

    More Infomation

    Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

    For Research Use Only. Not For Clinical Use.


    Creative Biolabs is a global leader in the fields of immunology and nephrology, and provides world-class anti-C3 recombinant antibodies (rAbs). Serving as the nexus of all three complement pathways, Complement C3 could be considered the most critical player in the entire system. Our elite antibodies to C3 are essential tools for exploring its function in an incredibly diverse range of diseases, from macular degeneration and C3 glomerulopathy to PNH and autoimmune disease.

    C3: The Central Convergence Point of Complement

    The key point of convergence for all three pathways: the classical pathway, the lectin pathway and the alternative pathway. Complement C3 is the most plentiful complement protein in plasma. Cleaved by enzymes common to all three pathways (C3 convertases), C3 is split into two extremely active fragments: the small anaphylatoxin C3a (a powerful pro-inflammatory molecule) and the large C3b fragment. C3b is the workhorse of the complement system. It covalently “tags” target surfaces for destruction (opsonization), and can also form the C5 convertase, which drives the remainder of the cascade. Dysregulation of C3 is a key driver of many diseases including C3 glomerulopathy (C3G) and age-related macular degeneration (AMD).

    Alternative Names

    ASP; C3a; C3b; AHUS5; ARMD9; CPAMD1; HEL-S-62p

    Background

    Complement component 3, often simply called C3, is a protein of the immune system. It plays a central role in the complement system and contributes to innate immunity.

    Protein class

    Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins

    Predicted location

    Intracellular, Secreted (different isoforms)

    Single cell type specificity

    Cell type enriched (Hepatocytes)

    Immune cell specificity

    Immune cell enriched (non-classical monocyte)

    Cell line specificity

    Group enriched (BJ hTERT+, EFO-21, Hep G2, HSkMC, SiHa)

    Interaction

    C3 precursor is first processed by the removal of 4 Arg residues, forming two chains, beta and alpha, linked by a disulfide bond. C3 convertase activates C3 by cleaving the alpha chain, releasing C3a anaphylatoxin and generating C3b (beta chain + alpha' chain). Forms the pro-C3-convertase enzyme complex by interacting with Complement factor B Bb fragment (Bb), which is then stabilized by binding CFP, allowing the complex to become active.

    More Types Infomation

    Anti-C3 rAb Products

    Our anti-C3 recombinant antibodies are optimized for high-affinity and high-performance. We have a full suite of antibodies, specific for C3, C3a, and the three major C3 fragments: C3b, iC3b and C3dg. Optimized for ELISA, Western Blot, and IHC applications for visualizing C3b deposition in diseased tissues (a telltale sign of complement attack), our rAbs are premier research and diagnostic tools.

    Table 1. Featured anti-C3 recombinant antibody products at Creative Biolabs.

    Cat. No. Product Name Target Species Host Species Applications
    ZG-0576J Rabbit Anti-C3 Recombinant Antibody (clone 4D12) Human Rabbit IgG ELISA, WB, IHC, FC
    HPAB-0064-FY Human Anti-C3 Recombinant Antibody (clone MOR9674) Human, Cynomolgus monkey Human IgG ELISA, Inhib
    NEUT-080CQ Mouse Anti-C3 Recombinant Antibody (clone K13/16) Human Mouse IgG1, κ ELISA, IP, WB, Neut

    Creative Quality Control

    At Creative Biolabs, quality is everything. Production of our anti-C3 fragment-specific antibodies is rigorously controlled by a quality assurance system. Purity, specificity, and consistent performance in well-validated diagnostic assay formats are guaranteed by extensive testing of each lot. You can trust Creative Biolabs to deliver a reliable reagent.

    Fig.1 IHC analysis. (Creative Biolabs Original)Fig.1 IHC analysis of anti-C3 antibody
    (Cat# ZG-0576J, Creative Biolabs).

    Fig.2 FC analysis. (Creative Biolabs Original)Fig.2 FC analysis of anti-C3 antibody
    (Cat# ZG-0576J, Creative Biolabs).

    Fig.3 ELISA analysis. (Creative Biolabs Original)Fig.3 ELISA analysis of anti-C3 antibody
    (Cat# HPAB-0064-FY, Creative Biolabs).

    Customer Reviews

    Excellent
    Gr**e
    Human Anti-C3 Recombinant Antibody (clone MOR9674)
    The quality of Creative Biolabs’ reagents is outstanding. Their anti-C3a ELISA pair is a staple in our lab for measuring systemic complement activation in plasma samples.
    18/Apr/2023

    rAb Production

    Accelerating progress in drug discovery is a key mission of Creative Biolabs, which is why we employ the latest production technologies. Our anti-C3 recombinant antibodies are optimized and screened with precision to deliver high-affinity, fragment-specific recognition that performs in the most challenging assays.

    Featured Anti-C3 Recombinant Antibody Production PlatformsFig.4 Milligram-scale. (Creative Biolabs Original)
    Fig.4 Milligram-scale anti-C3 recombinant antibody production.

    Fig.5 Gram-scale. (Creative Biolabs Original)Fig.5 Gram-scale anti-C3 recombinant antibody production.

    rAb Modalities

    Creative Biolabs is passionate about providing the research community with flexible and innovative research tools. Our anti-C3 antibodies are available in a variety of modalities, including potent functional blocking clones, and matched diagnostic ELISA pairs.

    Fig.6 C3 antibody production and modalities. (Creative Biolabs Original)Fig.6 Full-length anti-C3 recombinant antibody production and modalities.

    C3-Targeted Drug Information

    Table 2. Public drug targeting C3.

    Company Research Phase Classification Condition
    Apellis Pharma Approved Pegylated Peptide Inhibitor (Inhibits C3) Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Apellis Pharma Approved Pegylated Peptide Inhibitor (Inhibits C3) Geographic Atrophy (AMD)
    Novartis Approved Small Molecule (Inhibits Factor B) PNH (Targets alternative pathway C3 convertase)
    AstraZeneca (Alexion) Preclinical Monoclonal Antibody (Inhibitor) Complement-mediated diseases

    (Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)

    Target the epicenter of complement with Creative Biolabs’ fragment-specific anti-C3 recombinant antibodies. Our portfolio is engineered to deliver high-specificity and validation needed to diagnose and study an extensive range of complement-mediated diseases. Partner with us to access quality that can change medicine. Contact our specialists today.

    Related Diseases
    Systemic Lupus Erythematosus Systemic Lupus Erythematosus
    Go to compare

    Go to compare